Jo Lynne Rokita (Harenza)

Employment

• Children's National Hospital Director, Brain Tumor Institute Bioinformatics Core
  2024 - Present
• The Children's Hospital of Philadelphia Supervisory Bioinformatics Scientist
  2015 - 2024
• National Cancer Institute Research Collaborator
  2014 - 2015
• National Institute of Standards and Technology Research Biologist
  2013 - 2015

Education

• Virginia Commonwealth University Ph.D.
  2008 - 2013
• Arcadia University M.S.
  2006 - 2008
• Pennsylvania State University University Park B.S.
  2001 - 2005

Projects & Funding

Projects & funding information is unavailable.

Publications (63)

• Specific HLA Class I and II alleles are associated with a higher risk for tumor formation in Neurofibromatosis type 1
  2026 DOI: 10.64898/2026.05.04.26352173
  +Save
• The Open Pediatric Cancer Project
  2025 DOI: 10.1093/gigascience/giaf093
  +Save
• Supplementary Figure S1 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling
  2023 DOI: 10.1158/0008-5472.22422446.v1
  +Save
• Supplementary Table S1 from Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma
  2023 DOI: 10.1158/0008-5472.22424629
  +Save
• Supplementary Figure S2 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling
  2023 DOI: 10.1158/0008-5472.22422443.v1
  +Save
• Supplementary Figure S2 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling
  2023 DOI: 10.1158/0008-5472.22422443
  +Save
• Supplementary Figure S3 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling
  2023 DOI: 10.1158/0008-5472.22422440.v1
  +Save
• Supplementary Figure S3 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling
  2023 DOI: 10.1158/0008-5472.22422440
  +Save
• Supplementary Figure S4 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling
  2023 DOI: 10.1158/0008-5472.22422434.v1
  +Save
• Supplementary Figure S4 from YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling
  2023 DOI: 10.1158/0008-5472.22422434
  +Save